Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001407280
Ethics application status
Approved
Date submitted
17/08/2018
Date registered
22/08/2018
Date last updated
9/05/2024
Date data sharing statement initially provided
25/07/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of Continuous Positive Airway Pressure Mask Systems: Comparison of Cushions, Frames, Headgear, Components and Accessories for product development
Scientific title
Testing of Continuous Positive Airway Pressure (CPAP) masks on adult obstructive sleep apnea (OSA) patients to assess product usability and performance against benchmark products.
Secondary ID [1] 295836 0
MA17082018 & SLP-23-04-02
Universal Trial Number (UTN)
Trial acronym
Linked study record
This study is linked to ACTRN12614000998640. The current study is a continuation of the processes described in ACTRN12614000998640 with a new PI, new study sites, and minor methodological changes.

Health condition
Health condition(s) or problem(s) studied:
obstructive sleep apnea 309282 0
Condition category
Condition code
Respiratory 308155 308155 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
A variety of unregistered prototype CPAP masks will be used as the intervention in this study. The number of intervention masks a participant may test will range from 1 to 2 masks. There will be no washout period between masks. CPAP masks may be full face, nasal, or nasal pillows masks (covering mouth and nose, covering nose only, or inserted into nostrils).

As this study protocol aims to facilitate the product development of CPAP masks (an iterative process), this protocol allows for a prototype mask to be designed, used as a trial intervention, improved based on patient feedback, and then retested again as trial intervention. This process may occur for several cycles. This particular protocol also allows for the testing of several different prototype masks. As such, the total number of intervention masks being evaluated under this protocol at the beginning of the study is unknown, but will reported at the completion of the study.

All CPAP masks will be used for a minimum of 3 nights and a maximum of 7 nights. Other than 'mask type' setting, patient's CPAP therapy settings will not be changed.

Adherence will be monitored through data downloads directly from the patient's device or SD card. Adherence may also be monitored through an approved wireless therapy monitoring system (EasyCare Online).
Intervention code [1] 312169 0
Treatment: Devices
Comparator / control treatment
The comparator for this study will be one or more of the following:
- commercially available, approved CPAP mask currently used by the patient
- commercially available, approved CPAP mask not currently used by the patient
- another unapproved CPAP mask

The number of intervention masks a participant may test will range from 1 to 2 masks. There will be no washout period between masks.
Control group
Active

Outcomes
Primary outcome [1] 307127 0
Subjective mask usability including comfort, seal, and ease of use as assessed by patient questionnaire (ie. 11-point Likert scale designed for this protocol)
Timepoint [1] 307127 0
After a maximum of 7 nights
Primary outcome [2] 307128 0
Mask efficacy, as collected by Apnea-hypopnoea index downloaded by the CPAP device
Timepoint [2] 307128 0
After a maximum of 7 nights
Secondary outcome [1] 350771 0
Objective mask leak as assessed by CPAP device data
Timepoint [1] 350771 0
After a maximum of 7 nights

Eligibility
Key inclusion criteria
MA17082018 (2018-2023):

• Patients willing to give written informed consent
• Patients who can read and comprehend English
• Patients who >/= 18 years of age
• Patients being treated for OSA for >/= 6 months
• Patients currently using a suitable mask system
• Patients who can trial the masks for up to 7 nights each

SLP-23-04-02 (2023-2028):

• Participants willing to give written informed consent
• Participants who >/= 18 years of age
• Participants being treated for OSA for >/= 3 months
• Participants currently using a suitable mask system(s)
• Participants who can trial the masks for up to 7 nights each
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
MA17082018 (2018-2023):
• Patients using Bilevel flow generators
• Patients who are or may be pregnant
• Patients with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection; lung injury.
• Patients believed to be unsuitable for inclusion by the researcher
• Participants who or whose bed partner has implantable metallic implants in the head, neck and chest region affected by magnetic fields (Non-ferrous implants may be acceptable) (for masks with magnetic clips only)


SLP-23-04-02 (2023-2028):
• Patients using Bilevel flow generators
• Patients who are pregnant
• Patients with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection; lung injury.
• Patients believed to be unsuitable for inclusion by the researcher
• Patients who or whose bed partner has implantable medical devices which may contraindicate against masks with magnetic clips (exclusion criteria for study masks with magnetic clips only)
• Patients who are currently enrolled in other clinical studies

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/10/2018
Actual
15/11/2018
Date of last participant enrolment
Anticipated
23/10/2028
Actual
Date of last data collection
Anticipated
10/11/2028
Actual
Sample size
Target
60
Accrual to date
30
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 300432 0
Commercial sector/Industry
Name [1] 300432 0
ResMed Ltd
Country [1] 300432 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
ResMed Ltd
Address
1 Elizabeth Macarthur Drive, Bella Vista, NSW, 2120
Country
Australia
Secondary sponsor category [1] 299894 0
None
Name [1] 299894 0
Address [1] 299894 0
Country [1] 299894 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 301235 0
UNSW HREC
Ethics committee address [1] 301235 0
Ethics committee country [1] 301235 0
Australia
Date submitted for ethics approval [1] 301235 0
03/09/2018
Approval date [1] 301235 0
09/11/2018
Ethics approval number [1] 301235 0
HC18733
Ethics committee name [2] 315264 0
The University of New South Wales Research Ethics Committee A
Ethics committee address [2] 315264 0
Ethics committee country [2] 315264 0
Australia
Date submitted for ethics approval [2] 315264 0
23/06/2023
Approval date [2] 315264 0
09/08/2023
Ethics approval number [2] 315264 0
HC230403

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 86326 0
Dr Adam Benjafield
Address 86326 0
ResMed Ltd. 1 Elizabeth Macarthur drive, Bella Vista, NSW 2153
Country 86326 0
Australia
Phone 86326 0
+61 2 8884 1000
Fax 86326 0
Email 86326 0
[email protected]
Contact person for public queries
Name 86327 0
Alison Wimms
Address 86327 0
ResMed Ltd. 1 Elizabeth Macarthur drive, Bella Vista, NSW 2153
Country 86327 0
Australia
Phone 86327 0
+61 2 8884 1000
Fax 86327 0
Email 86327 0
[email protected]
Contact person for scientific queries
Name 86328 0
Alison Wimms
Address 86328 0
ResMed Ltd. 1 Elizabeth Macarthur drive, Bella Vista, NSW, 2153
Country 86328 0
Australia
Phone 86328 0
+61 2 8884 1000
Fax 86328 0
Email 86328 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
company confidential data, no benefit for sharing IPD


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.